DAX ®12.511,91-1,44%TecDAX ®2.799,07+0,01%S&P FUTURE2.760,60+0,29%Nasdaq 100 Future7.250,75+0,18%
WM Tippspiel
teilnehmen und gewinnen

DGAP-Adhoc: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: WILEX AG / Key word(s): Alliance
WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research
Agreement with Takeda for the Development of Antibody Targeted Amanitin

19-Jun-2017 / 17:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Ad-hoc release *

Insider information pursuant to Article 17 MAR

*WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target
Research Agreement with Takeda for the Development of Antibody Targeted
Amanitin Conjugates *

*Munich, Germany, 19 June 2017 -* WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that its subsidiary, Heidelberg Pharma GmbH, Ladenburg,
Germany, has signed an exclusive multi-target research agreement with Takeda
Pharmaceutical Company Limited (TSE: 4502) for the joint development of
antibody drug conjugates (ADCs) that use Amanitin as the payload.

Under the terms of the exclusive multi-target research agreement, Heidelberg
Pharma will produce Antibody Targeted Amanitin Conjugates (ATACs) using
antibodies from Takeda's proprietary portfolio for up to three undisclosed
targets. Takeda has an option for an exclusive license for global
development and commercialization rights to each of the product candidates
resulting from the research collaboration. If it exercises the option,
Takeda would be responsible for further preclinical and clinical
development, as well as potential commercialization, of any product
candidate it licenses.

Heidelberg Pharma will receive an upfront technology access fee and payments
for research services. In the event Takeda exercises its option for an
exclusive license, Heidelberg Pharma would receive an option fee. Under the
exclusive license agreement, Heidelberg Pharma would be eligible to receive
clinical development, regulatory and sales-related milestone payments of up
to USD 113 million for each product candidate, as well as royalties.

The expected financial impact of this partnership is already reflected in
WILEX's financial outlook for the current fiscal year provided in March

Takeda signed the agreement with Heidelberg Pharma through its wholly-owned
subsidiary, Millennium Pharmaceuticals, Inc.

+++ End of the Ad Hoc-Release +++

*About Heidelberg Pharma's proprietary ATAC technology*
Antibody-drug conjugates (ADCs) combine the high affinity and specificity of
antibodies with the potency of cytotoxic small molecules for the treatment
of cancer and inflammatory diseases. Antibody Targeted Amanitin Conjugates
(ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.
Amatoxins are small bicyclic peptides naturally occurring in the death cap
mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a
mechanism that is crucial for the survival of eukaryotic cells. In
preclinical testing, ATACs have been shown to be highly efficacious,
overcoming frequently encountered resistance mechanisms and combating even
quiescent tumor cells.

*About WILEX and Heidelberg Pharma*
WILEX AG is a biopharmaceutical company based in Munich, Germany, that
serves as a parent and holding company. The Company's research and
development work is conducted by its subsidiary Heidelberg Pharma GmbH based
in Ladenburg. Heidelberg Pharma is the first company to develop the toxin
Amanitin for use in cancer therapies using its proprietary Antibody Targeted
Amanitin Conjugate (ATAC) technology and to advance the biological mode of
action of the toxin as a novel therapeutic principle. This proprietary
technology platform is being applied to develop the company's own
therapeutic ATACs as well as in third-party collaborations to create a
variety of ATAC candidates. The proprietary lead candidate is a BCMA ATAC
for multiple myeloma. WILEX's clinical assets MESUPRON(R) and REDECTANE(R)
have been partnered, while RENCAREX(R) is available for out-licensing and
further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at

*Contact * *IR/PR support*
Sylvia Wimmer Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-29 Managing Director & Partner
Email: investors[at]wilex.com Tel.: +49 89-210 228-40
Grillparzerstr. 18, 81675 Munich, Email:
Germany katja.arnold[at]mc-services.

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

19-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: WILEX AG
Grillparzerstr. 18
81675 München
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart,
Tradegate Exchange

End of Announcement DGAP News Service

584219 19-Jun-2017 CET/CEST

(END) Dow Jones Newswires

June 19, 2017 11:14 ET ( 15:14 GMT)



Aktuelle Videos

zur Mediathek
Börsenseminare: Investieren Sie in Ihre Bildung!

Börse Stuttgartschliessen
Börse Stuttgart


Wo bieten sich Anlegern weltweit die besten Wachstumschancen? Wir stellen im neuen Anlegermagazin vier Titel mit viel Potenzial vor.

Jetzt kostenlos anmelden!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Bei wikifolio können Sie die Performance von privaten und professionellen Tradern nachhandeln. Interessiert Sie das?
Jetzt abstimmen!
Alle Umfragen ansehen